CDC25 Phosphatase Inhibitor I

CAS No. 396073-89-5

CDC25 Phosphatase Inhibitor I( BN-82002 | CDC25 Phosphatase Inhibitor I | PTP Inhibitor XX | )

Catalog No. M19377 CAS No. 396073-89-5

BN82002 is a synthetic inhibitor of CDC25 phophatases.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 80 In Stock
10MG 110 In Stock
25MG 200 In Stock
50MG 335 In Stock
100MG 500 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    CDC25 Phosphatase Inhibitor I
  • Note
    Research use only, not for human use.
  • Brief Description
    BN82002 is a synthetic inhibitor of CDC25 phophatases.
  • Description
    BN-82002, also known as CDC25 Phosphatase Inhibitor I, is a cell-permeable ortho-hydroxybenzylamino compound that displays anti-tumor properties. BN-82002 acts as a potent, selective, and irreversible inhibitor of CDC25 phosphatase family (IC50 = 2.4, 3.9, 6.3, 5.4, and 4.6 μM for 25A, 25B2, 25B3, 25C, and 25C-cat, respectively). BN82002 inhibits the phosphatase activity of recombinant human CDC25A, B, and C in vitro. It impairs the proliferation of tumoral cell lines and increases cyclin-dependent kinase 1 inhibitory tyrosine phosphorylation. In synchronized HeLa cells, BN82002 delays cell cycle progression at G1-S, in S phase and at the G2-M transition.
  • In Vitro
    The effect of BN82002 on cell proliferation is evaluated in vitro on several human tumor cell lines. Menadione, which has been reported to inhibit cell proliferation, is used as a control. All of the examined cell lines are sensitive to BN82002 and Menadione in a concentration-dependent manner in the low micromolar range. The most sensitive is the pancreatic cancer cell line MIA PaCa-2 with an IC50 of 7.2 μM, and the less sensitive cell line is the colon cancer HT-29 with an IC50 of 32.6 μM. The range of activity is very similar to the one observed with menadione (5-15 μM). It is also showed that 50 μM BN82002 is a concentration that fully inhibits cell proliferation, the cell cycle distribution is only modestly affected with a slight decrease in S phase and an increase in cells containing both a G1 and a G2 DNA content, suggesting that the cells treated with BN82002 are arrested at various stages of the cell cycle.
  • In Vivo
    ——
  • Synonyms
    BN-82002 | CDC25 Phosphatase Inhibitor I | PTP Inhibitor XX |
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    Phosphatase
  • Recptor
    CDC25A|CDC25B2|CDC25B3|CDC25C|CDC25C-cat
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    396073-89-5
  • Formula Weight
    359.42
  • Molecular Formula
    C19H25N3O4
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : ≥ 150 mg/mL; 417.34 mM
  • SMILES
    Oc1c(cc(cc1OC)N(C)C)CN(C)CCc2ccc(cc2)[N+]([O-])=O
  • Chemical Name
    Phenol, 4-(dimethylamino)-2-methoxy-6-((methyl(2-(4-nitrophenyl)ethyl)amino)methyl)-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Brezak MC, et al. A novel synthetic inhibitor of CDC25 phosphatases: BN82002. Cancer Res. 2004 May 1;64(9):3320-5.
molnova catalog
related products
  • h-NTPDase-IN-3

    h-NTPDase-IN-3 is an h-NTPDase inhibitor that inhibits h-NTPDase1, h-NTPDase2, h-NTPDase3 and h-NTPDase8.

  • DJ001

    DJ001 is a highly specific, selective, and non-competitive protein tyrosine phosphatase σ (PTPσ) inhibitor with an IC50 of 1.43 μM, and it promotes the regeneration of hematopoietic stem cells.

  • PTP1B-IN-3

    PTP1B-IN-3 is a selective and potent PTP1B inhibitor with anticancer activity that inhibits PTP1B and TCPTP.PTP1B-IN-3 is used in the study of diabetes.